CAP-SCORE™ Sperm Function Test **Patient Report**

Androvia LifeSciences
187 Mill Lane, Mountainside, NJ 07092
Ph: 866-833-7845
CLIA: 31D2115698 · CAP: 9443749 · NYS: PFI9256
info@androvialife.com · www.androvialifesciences.com

Patient name: Doe, John		**Date of birth:** 01-02-1983
Requested by: Jane Smith, MD		**Specimen ID:** 20001111
Date collected: 06-18-18	**Date received:** 06-19-18	**Date reported:** 06-19-18

	Result	Reference Range	Interpretation
Cap-Score™	40%	>27.6%	NORMAL
Probability of Generating a Pregnancy	56%	> 32.7%	NORMAL

Interpretation:

By assessing the percentage of sperm capable of undergoing capacitation, the Cap-Score™ provides an assessment of a patient's ability to generate a pregnancy. Patients with Cap-Scores lower than one standard deviation below the mean of a population of fertile men are defined as LOW (≤ 27.6%). In a prospective study, a cohort of men with Cap-Scores greater than 27.6% had 4x more clinical pregnancies within one attempt, 3x more pregnancies within two attempts, and 2x more pregnancies within three attempts compared to men with LOW Cap-Scores (cite manuscript). Male fertility represents a continuum, and the relationship between Cap-Score and the probability of generating a pregnancy was developed and tested using data from multiple clinics. The graphic illustrates your patient's relative fertility and corresponding probability of generating a pregnancy within three attempts (Red Star).



Disclaimer:

Cap-Score and probability of generating a pregnancy (PGP) should be interpreted in the context of both a semen analysis and a complete medical work-up of both the male and female couple. The Cap-Score and PGP should never be used as the sole criterion in the determination of male fertility. A LOW result may be transient in nature, influenced by factors occurring prior to, during and after sample collection and preparation. If the treatment plan allows, it is recommended to repeat the Cap-Score test in three months. The performance characteristics of this test were determined by Androvia LifeSciences. It has not been cleared or approved by the U.S. Food and Drug Administration. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

Performed by: Melissa Moody, Laboratory Supervisor

Approved by: Romeo Mendoza, Laboratory Supervisor

Laboratory Director: Bryan Kloos, PhD, HCLD

Reference Placed Here